|
1.Alagoz T, Buller RE, Anderson B, Terrell KL, Squatrito RC, Niemann TH, Tatman DJ, Jebson P:Evaluation of hyperbaric oxygen as a chemosensitizer in the treatment of epithelial ovarian cancer in xenografts in mice. Cancer, 75 (9):2313-22, 1995. 2.Belozerov VE and Van Meir EG:Hypoxia inducible factor-1:a novel target for cancer therapy. Anti-cancer Drugs, 16:901-909, 2005. 3.Brown JM: The hypoxic cell:a target for selective cancer therapy. Cancer Res. 59:5863-70, 1999. 4.Bojes HK, Datta K, XU J, Chin A, Simonianp, Nunn EZ G, and Kehrer JP:Bcl-xL overexpression attenuates glutathione depetion in FL5.12 cells following interleukin-3 withdrawal. Biochem J. 325 (2):315-319, 1997. 5.Brenner I, Shephard JR and Shek NP:Immune function in hyperbaric environments, diving, and decompression. Undersea Hyperb. Med. 26 (1):27-39, 1999. 6.Camp RL, Rimm EB, and Rimm, DL:Met expression is associated with poor outcome in patients with axillary lymph node negative breast carcinoma. Cancer. 86:2259-2265, 1999. 7.Chavko M, Braisted JC, Outsa NJ, and Harabin AL:Role of cerebral blood flow in seizures from hyperbaric oxygen exposure. Brain Res. 791:75-82, 1998. 8.Christofori G:New signals from the invasive front. Nature. 441(25):444-450, 2006. 9.Feldmeier JJ, Onoda JM, Bossung DE, Court WS, and Alecu R:Effect of hyperbaric oxygen on cancer cell metastatic potential and proliferation. Undersea Hyper Med. 24(supl):130, 1997. 10.Feldmeier JJ, Hampson NB. A systematic review of the literature reporting the application of hyperbaric oxygen prevention and treatment of delayed radiation injuries:an evidence-based approach. Undersea & Hyperbaric Medicine (UHM), 29:4–30, 2002. 11.Feldmeier J, Carl U, Hartmann K, Sminia, P: Hyperbaric oxygen:Dose it promote growth or recurrence of malignancy? Undersea & Hyperbaric Medicine (UHM), 30(1):1-18, 2003. 12.Ferrara N, Davis-Smyth T:The biology of vascular endothelial growth factor. Endocrine reviews, 18:4-25, 1997. 13.Francis, JT, Griffin LJ, Homer DL, Pezeshkpour HG, Dutka JA and Flynn TE:Bubble-induced dysfunction in acute spinal cord decompression sickness. J Appl. Physiol. 68(4):1368-75, 1990. 14.Freeman BA, Topolosky MK, and Crapo JD:Hyperoxia increase radical production in rat lung homogenates. Arch Biochem Biophys. 216:477-484, 1982. 15.Folkman J:Tumor angiogenesis: Therapeutic implications. N Engl. J Med., 285:1182-1186, 1971. 16.Folkman J:What is the evidence that the tumors are angiogenesis dependent? J Natl. Cancer Inst., 82:4-6, 1990. 17.Folkman J:Clinical applications of research on angiogenesis. N Engl J Med, 333:1757-1763, 1995. 18.Folkman J:Role of Angiogenesis in Tumor Growth and Metastasis. Seminars in Oncology., 29(6), Suppl. 16 (December):15-18, 2002. 19.Gale NW, Yancopoulos GD:Growth factors acting via endothelial cell-specific receptor tyrosine kinases: VEGFs, angiopoietins, and ephrins in vascular development. Gene & development, 13:1055-1066, 1999. 20.Ghoussoub RA, Dillon DA, D’Aquila T, Rimm EB, Fearon ER, and Rimm D L:Expression of c-met is a strong independent prognostic factor in breast carcinoma. Cancer. 82:1513-1520, 1998. 21.Greco O, Marples B, Joiner MC, Scott SD:How to overcome (and exploit) tumor hypoxia for targeted gene therapy. Journal of Cellular Physiology, 197:312-325, 2003. 22.Grim PS, Gottlieb LJ, Boddie A, and Batson E:Hyperbaric oxygen therapy. JAMA. 263: 2216-2220, 1990. 23.Hansbrough JF, Piacentine JG, and Eiseman B:Immunosuppression by hyperbaric oxygen. Surg. 87:662-667, 1980. 24.Hockel M, and Vaupel P:Tumor hypoxia: definitions and current clinical, biologic, and molecular aspects. J N C I. 93 (4):266-276, 2001. 25.Houck KA, Leung DW, Rowland AM, Winer J, Ferrara N:Dual regulation of vascular endothelial growth factor bioavailability by genetic and proteolytic mechanisms. J. Biol. Chem., 267:26031-26037, 1992. 26.Huang LE, Gu. J, Schau M, and Bunn HF:Regulation of hypoxia-inducible factor l alpha is mediated by an O2-dependent degradation domain via ubiquitin-proteasome pathway. Proc. Natl. Acad. Sci. 95:7987-92, 1998. 27.Hunt, TK:Zederfeldt B, Goldtick TK:The Oxygen and Healing. Am. J. Surg. 118:521-5, 1969. 28.Hunt, TK:The physiology of wound healing. Ann Emerg Med. 17(12):1265-73, 1988. 29.Ito T, Yufu K, Mori A, and Packer L:Oxidative stress alters arginine metabolism in rat brain: effect of sub-convulsive hyperbaric oxygen exposure. Neurochem Int. 29(2):187-95, 1996. 30.Jain KK:Textbook of hyperbaric medicine. Flagstaff, AZ:Best Publishing, 1996. 31.Jain KK:Textbook of hyperbaric medicine:Indications, contraindications, and complications of hyperbaric oxygen therapy, 103-109, 2004. 32.Johnson RJR, and Lauchlan SC:Epidermoid carcinoma of the cervix treated by 60Co therapy and hyperbaric oxygen. Proceedings of the third international congress on hyperbaric medicine. 648-52, 1966. 33.Kaelin CM, Im MJ, Myers RAM, Manson PN, and Hoopes JE:The effects of hyperbaric oxygen on free flaps in rats. Arch Surg. 125:607-9, 1990. 34.Kallio PJ, Wilson WJ, O’Brien S, Makino Y, and Poellinger L:Regulation of the hypoxia-inducible transcription factor l alpha by the ubiquitin-proteasome pathway. J. Biol. Chem. 274:6519-25, 1999. 35.Kaln J, Krock L, and Piepmeier E:The effect of hyperbaric oxygen on growth and chemosensitivity of metastatic prostate cancer. Anticancer Res. 18:363-7, 1998. 36.Klagsbrun V, D’Amore PA:Vascular endothelial growth factor and its receptors. Cytokine & growth factor reviews, 7(3):259-270, 1996. 37.Knighton, DR, Halliday B and Hunt TK:Oxygen as an antibiotic. A comparison of the effects of inspired oxygen concentration and antibiotic administration on in vivo bacterial clearance. Arch Surg. 121(2):191-5, 1986. 38.Kinoshita Y, Kohshi K, Kunugita N, Tosaki T and Yokota A:Preservation of tumour oxygen after hyperbaric oxygenation monitored by magnetic resonance imaging. British Journal of Cancer, 82(1):88–92, 2000. 39.Lemarie RJ, Hosgood G, VanSteenhouse J, Hodgin EC, Tedford BL, and Strain GM:Effect of hyperbaric oxygen on lipid peroxidation in free skin grafts in rats. Am J Vet Res., 59(7):913-7, 1998. 40.Li H, Shimura H, Aoki Y, Date K, Matsumoto K, Nalamura T, and Tanaka M:Hepatocyte growth factor stimulates the invasion of gallbladder carcinoma cell lines in vitro. Clin. Exp. Meta. 16:74-82, 1998. 41.Livio Trusolino and Paolo M. Comoglio:Scatter-Factor and semaphoring receptors:cell signaling for invasive growth. Nature Reviews, 2:289-300, 2002. 42.Cejudo-Martin P and Johnson RS:A new notch in the HIF belt: How hypoxia impacts differentiation. Development Cell, 9:575-576, 2005. 43.Marx RE:Radiation injury to tissue. In: Kindwall EP., Whelan HT. (cds) Hyperbaric Medicine Practice (Second Edition). Flagstaff, AZ:Best Publishing Co., 720, 1999. 44.McMillan T, Calhoun KH, Mader JT, Stiernberg CM, Rajarman S:The effect of hyperbaric oxygen on oral mucosal carcinoma. Laryngoscope, 99:241-244, 1989. 45.Menon C, Fraker DL:Tumor oxygenation status as a prognostic marker. Cancer Letters, 221:225–235, 2005. 46.Nakajima M, Sawada H, Yamada Y, Watanabe A, Tatsumi M, and Yamashita J:The prognostic significance of amplification and overexpression of c-met and c-erb B-2 in human gastric carcinomas. Cancer. 85:1894-902, 1999. 47.Neufeld G, Cohen T, Gengrinovitch S, Poltorak Z.:Vascular endothelial growth factor (VEGF) and its receptors. FASEB J, 13:9-22, 1999. 48.Oliner J et al.:Suppression of angiogenesis and tumor growth by selective inhibition of angiopoietin-2. Cancer Cell, 6:507-516, 2004. 49.O’Reilly MS, Holmgren L, Folkman JC. Chen:Angiostatin induces and sustains dormancy of human primary tumors in mice, Nat. Med., 2:689–692, 1996. 50.Oriani G, Marroni A, Wattel F, et al.:Physiology and physiopathology of hyperbaric oxygenation. Handbook on hyperbaric medicine, Springer, 1996, 1-34. 51.Padgaonkar VA, Leverenz VR, Fowler KE, Reddy VN, and Giblin FJ:The effects of hyperbaric oxygen on the crystallins of cultured rabbit lenses: a possible catalytic role for copper. Exp Eye Res. 71(4):371-83, 2000. 52.Parr C, Watkins G, Mansel RE, and Jiang WG:The hepatocyte growth factor regulatory factors in human breast cancer. Clinical Cancer Res. 10:202-211, 2004. 53.Pennacchietti S, Michieli P, Galluzzo M, Mazzone M, Giordano S, and Comoglio PM:Hypoxia promotes invasive growth by transcriptional activation of the met protoocogene. Cancer Cell, 3:347-61, 2003. 54.Purucker E, and Lutz J:Effect of hyperbaric oxygen treatment and perfluorochemical administration on glutathione status of the lung. Adv Exp Med Biol, 317:131-6, 1992. 55.Rapisarda A, Zalek J, Hollingshead M, Braunschweig T, Uranchimeg B, Bonomi CA, Borgel SD, Carter JP, Hewitt SM, Shoemaker RH, and Melillo1 G:Schedule-dependent inhibitionn of hypoxia-inducible factor-1 protein accumulation, angiogenesis, and tumor growth by Topotecan in U251-HRE glioblastoma xenografts. Cancer Res. 64:6845–6848, 2004. 56.Salceda S, and Caro J:Hypoxia-inducible factor 1 (HIF-1) protein is rapidly degraded by the ubiquitin-proteasome system under normoxic conditions. J. Biol. Chem. 272:22642-7, 1997. 57.Semenza GL:Targeting HIF-1 for cancer therapy. Nature Reviews Cancer. 3:721-732, 2003. 58.Sheridan RL, and Shank ES:Hyperbaric Oxygen Treatment:A Brief Overview of a Controversial Topic. J. Trauma. 47:426-35, 1999. 59.Shewell J, and Thompson SC:The effect of hyperbaric oxygen treatment on pulmonary metastasis in the C3H mouse. Eur J Cancer. 16:253-9, 1980. 60.Shi Y, Lee CS, Wu J, Koch CJ, Thom ST, Maity A, Bernhard EJ:Effects of hyperbaric oxygen exposure on experimental Head and Neck tumor growth, oxygenation, and vasculature. Head and Neck, 27:362-369, 2005. 61.Speit G and Bonzheim I:Genotoxic and protective effects of hyperbaric oxygen in A549 lung cells. Mutagenesis 18(6):545-548, 2003. 62.Sun TB, Chen RL, Hsu YH:The effect of hyperbaric oxygen on human oral cancer cells. Undersea & Hyperbaric Medicine, 31(2):251-260, 2004. 63.Sugawara J, Fukaya T, Murakami T, Yoshida H, and Yajima A:Hepatocyte growth factor stimulates proliferation, migration, and lumen formation of human endometrial epithelial cells in vitro. Biology of reproduction. 57:936-942, 1997. 64.Suzuki Y, Ono Y, and Hirabayashi Y:Rapid and specific reactive oxygen species generation via NADPH oxidase activation during Fas-mediated apoptosis. FEBS Lett. 425(2):209-12, 1998. 65.Takiguchi N, Saito N, Nunomura M, Kouda K, Oda K, Furutyama N, Nakajima N: Use of 5-FU plus hyperbaric oxygen for treating malignant tumors: evaluation of antitumor effect and measurement of 5-FU in individual organs. Cancer Chemother. Pharmacol., 47:11-14, 2001 66.Taniguchi K, Yonemura Y, Nojima N, Hirono Y, Fushida S and Fujimura T:The relation between the growth patterns of gastric carcinoma and the expression of hepatocyte growth factor receptor (c-met), autocrine motility factor receptor, and urokinase-type plasminogen activator receptor. Cancer, 82:2112-22, 1998. 67.Thomlinson RH and Gray LH:The histological structure of some human lungcancers and the possible implications for radiotherapy. Br. J. Cancer, 9:539–549, 1955. 68.Tibbles PM and Edelsberg JS:Medical progress: Hyperbaric-oxygen therapy. The N Engl J Med. 334(25):1642-8, 1996. 69.Trusolino L and Comoglio PM:Scatter-factor and semaphorin receptors: Cell signaling for invasive growth. Nature reviews cancer. 2:289-300, 2002. 70.Ueki T, Fujimoto J, Suzuki T, Yamamoto H, and Okamoto E:Expression of hepatocyte growth factor and its receptor c-met proto-oncogene in hepatocellular carcinoma. Hepatology. 25:862-6, 1997. 71.Veikkola T, Karkkainen M, Lena CW, Alitalo K:Regulation of angiogenesis via vascular endothelial growth factor receptors. Cancer Research, 60:203-212, 2000. 72.Wang G.L, and Semenza GL:Purification and characterization of hypoxia-inducible factor 1. J. Biol. Chem. 270:1230-7, 1995. 73.Zhou J, Schmid T, Schnitzer S, Brüne Bernhard:Tumor hypoxia and cancer progression. Cancer Letters, 1–12, 2005.
|